Neuropharmacology & Neurotherapeutics
Rasagiline is indicated in the treatment of Parkinson disease, both as initial monotherapy in patients with early Parkinson disease and as adjunct to levodopa treatment in moderate-to-advanced Parkinson disease. The aim of rasagiline is neuroprotection and to slow the progression of Parkinson disease. Rasagiline should not be taken by patients with moderate to severe hepatic impairment or pheochromocytoma.
Oct. 15, 2021